Smith & Nephew plc (LON:SN - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,055.89 ($14.18) and traded as high as GBX 1,140 ($15.31). Smith & Nephew shares last traded at GBX 1,122.50 ($15.07), with a volume of 1,274,729 shares traded.
Smith & Nephew Trading Down 0.3%
The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The firm has a 50 day moving average price of GBX 1,088.48 and a two-hundred day moving average price of GBX 1,055.89. The company has a market cap of £12.27 billion, a price-to-earnings ratio of 40.29, a PEG ratio of 0.46 and a beta of 0.62.
Insider Activity at Smith & Nephew
In other news, insider Jeremy (Jez) Maiden purchased 1,855 shares of the business's stock in a transaction on Thursday, May 1st. The shares were acquired at an average price of GBX 1,070 ($14.37) per share, for a total transaction of £19,848.50 ($26,649.44). 0.19% of the stock is currently owned by insiders.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
